Last reviewed · How we verify
Rapamune and Prograf
Rapamune and Prograf is a Small molecule drug developed by Wayne State University. It is currently FDA-approved.
Rapamune and Prograf are small molecule immunosuppressants used in the treatment of various conditions, including Type 1 Diabetes, Islet Transplantation, End Stage Renal Failure With Renal Transplant, End-Stage Renal Disease, and Kidney Failure. They are used as maintenance immunosuppressive treatment, often in combination with other medications such as MMF or tacrolimus, to prevent organ rejection in patients with renal transplants.
At a glance
| Generic name | Rapamune and Prograf |
|---|---|
| Sponsor | Wayne State University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (PHASE3)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (PHASE2)
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) (PHASE2)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- Advancing Transplantation Outcomes in Children (PHASE2)
- HLA-Identical Sibling Renal Transplant Tolerance (NA)
- Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rapamune and Prograf CI brief — competitive landscape report
- Rapamune and Prograf updates RSS · CI watch RSS
- Wayne State University portfolio CI
Frequently asked questions about Rapamune and Prograf
What is Rapamune and Prograf?
Who makes Rapamune and Prograf?
What development phase is Rapamune and Prograf in?
Related
- Manufacturer: Wayne State University — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing